Definitive Contract HHS261015140

Award Date 9/30/04
Potential Completion Date 6/30/05
Potential Value $232K
Funding Federal Agency
Not listed
Contracting Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Illinois, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $119,495.00 firm fixed-price Purchase Order is for a 14-day dose range finding study in mice to support Investigational New Drug (IND) applications. IITRI has extensive experience conducting preclinical drug development services, including toxicology,...
This federal contract award, valued at $698,236.00, was issued to the Illinois Institute of Technology Research Institute (IITRI), a non-profit organization, by a U.S. government agency. The contract is a Definitive Contract with a Firm Fixed Price pricing type. It does not have a set-aside designation. IITRI is a preclinical contract research organization (CRO) that provides a wide range of services to pharmaceutical, biotechnology, and government clients, including the National Institutes of...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $159,319,089.46 contract, which does not have a set-aside designation, is for preclinical toxicology and pharmacology studies to support Investigational New Drug (IND) applications for small molecule, biologic, and RNA therapeutic candidates across various...
The National Cancer Institute (NCI) awarded a $1,886,133.00 delivery order contract to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology. The contract is for toxicology studies in rats and dogs administered the compound AIT-102. The award is not associated with a set-aside designation. IITRI is a contract research organization that specializes in preclinical drug development services, including pharmacology, toxicology, safety, and efficacy...
This is a $631,772.00 delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for toxicology studies on reproductive effects in rats, supporting the NCCIH (National Center for Complementary and Integrative Health) program. This is a cost-plus-fixed-fee contract that was not set aside for any type of small...
This is a $1,790,042.00 Delivery Order Contract awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit subsidiary of the Illinois Institute of Technology (IIT). The contract is for toxicology studies in mice and dogs administered MTX-531, which does not have a set-aside designation. IITRI is a leading preclinical contract research organization that specializes in providing drug development services to federal agencies like the NCI, NIAID, NINDS, and...
This federal contract award, valued at $33,483,214.15, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for preclinical pharmacology and toxicology studies to support the development of small molecule, biologic, and RNA therapeutic candidates across various disease areas. IITRI has extensive experience providing these services to...
This is a federal contract award issued by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology. The $224,716.00 contract is a delivery order under a larger indefinite delivery/indefinite quantity (IDIQ) vehicle called the Pharmacology and Toxicology for Therapeutics Program, which has a total ceiling value...
This federal contract award to IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology, is for $212,495.00 under the National Institute of Neurological Disorders and Stroke's (NINDS) Pharmacology and Toxicology for Therapeutics Program. The contract, awarded on March 1, 2024, is a firm fixed-price delivery order that runs through September 12, 2026. IITRI has extensive experience supporting the Department of Health and Human Services through preclinical drug...
This federal contract award is for $2,708.00 to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology (IIT), to provide contract orientation and kickoff meeting services for R&D under the "Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications" program. The contract is being issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. IITRI...

This is a federal contract awarded by the U.S. Department of Health and Human Services (HHS) to the Illinois Institute of Technology Research Institute (IITRI), a non-profit contract research organization. The contract, valued at $231,502, is for preclinical toxicology studies of chemopreventive agents in dogs under work order #62. The contract is a definitive, firm-fixed price contract with a completion date of June 30, 2005. IITRI specializes in conducting pharmacology, toxicology, safety, and efficacy evaluations to support Investigational New Drug (IND) applications for federal agencies, primarily within HHS. The contract is not designated as a set-aside. IITRI has been awarded numerous prime and subcontracts from agencies such as the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), and National Center for Advancing Translational Sciences (NCATS) to support a wide range of preclinical research activities.

Generated 9/30/24, 11:11 AM